Manufacturer High Purity 99% Semaglutide Weight Loss Injections Peptide CAS No. 910463-68-2 10ml/Vials

Product Name Semaglutide

Cas No. C187H291N45O59

Sequence H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH

Molecular Formula C187H291N45O59

Molar Mass  4,113.64 g·mol

Purity ≥98%

Impurity  ≤0.5% 

Storage Temperature  2-8ºC

Packing Size 1G/Bottle, 10G/Bottle,50G/Bottle or at customers reqirement.

Unlock the potential of Semaglutide for weight loss and more! 

Here's why it's making waves in the health world.

Benefits of Semaglutide:

Blood sugar control: Semaglutide, a GLP-1 receptor agonist, lowers blood sugar levels in type 2 diabetes by boosting insuline secretion and reducing liver glucose production.

Weight loss: Semaglutide aids weight loss by curbing appetite and slowing digestion, benefiting those with obesity.

Cardiovascular benefits: Studies suggest semaglutide may reduce cardiovascular risks beyond its effects on blood sugar and weight.

Lower risk of Hypoglycemia: Semaglutide minimizes hypoglycemia due to its glucose-dependent insuline stimulation.

 

Semaglutide helps those works by mimicking a hormone called glucagon-like peptide-1 (GLP-1) that targets areas of the brain that regulate appetite and food intake. Semaglutide safety and efficacy were studied in four 68-week trials. Three were randomized, double-blind, placebo-controlled trials (including 16 weeks of dose increases) and one was a double-blind, placebo-controlled, randomized withdrawal trial in which patients receiving Semaglutide either continued with the treatment or switched to a placebo. More than 2,600 patients received Semaglutide for up to 68 weeks in these four studies and more than 1,500 patients received placebo.

The largest placebo-controlled trial enrolled adults without diabetes. The average age at the start of the trial was 46 years and 74% of patients were female. The average body weight was 231 pounds (105 kg) and average BMI was 38 kg/m2. Individuals who received Semaglutide lost an average of 12.4% of their initial body weight compared to individuals who received placebo. Another trial enrolled adults with type 2 diabetes. The average age was 55 years and 51% were female. The average body weight was 220 pounds (100 kg) and average BMI was 36 kg/m2. In this trial, individuals who received Semaglutide lost 6.2% of their initial body weight compared to those who received placebo.